Rapid Micro Biosystems (RPID) Stock Price, News & Analysis

Company Overview

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.

Key Stats

• Today's Range: $2.86 to $3.34
• 50-Day Range: $1.98 to $3.16
• 52-Week Range: $0.58 to $4.04
• Volume: 342,290 shs
• Average Volume: 185,980 shs
• Market Capitalization: $136.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Strong Buy

Rapid Micro Biosystems Stock Analysis - MarketRank™

Rapid Micro Biosystems scored higher than 32% of companies evaluated by MarketBeat, and ranked 790th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Strong Buy

Amount of Analyst Coverage

Rapid Micro Biosystems has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rapid Micro Biosystems are expected to grow in the coming year, from ($1.10) to ($0.94) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rapid Micro Biosystems is -2.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rapid Micro Biosystems is -2.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rapid Micro Biosystems has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.95% of the float of Rapid Micro Biosystems has been sold short.

Short Interest Ratio / Days to Cover

Rapid Micro Biosystems has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rapid Micro Biosystems has recently decreased by 10.56%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rapid Micro Biosystems does not currently pay a dividend.

Dividend Growth

Rapid Micro Biosystems does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.95% of the float of Rapid Micro Biosystems has been sold short.

Short Interest Ratio / Days to Cover

Rapid Micro Biosystems has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rapid Micro Biosystems has recently decreased by 10.56%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.17

News Sentiment

Rapid Micro Biosystems has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Rapid Micro Biosystems this week, compared to 1 article on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rapid Micro Biosystems insiders have not sold or bought any company stock.

Percentage Held by Insiders

29.96% of the stock of Rapid Micro Biosystems is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

52.60% of the stock of Rapid Micro Biosystems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RPID Stock Analysis - Frequently Asked Questions

How have RPID shares performed this year?

Rapid Micro Biosystems' stock was trading at $0.90 on January 1st, 2025. Since then, RPID stock has increased by 251.1% and is now trading at $3.16.
View the best growth stocks for 2025 here.

How were Rapid Micro Biosystems' earnings last quarter?

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) issued its quarterly earnings results on Friday, May, 9th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.01. The company had revenue of $7.21 million for the quarter, compared to analyst estimates of $6.63 million. Rapid Micro Biosystems had a negative trailing twelve-month return on equity of 48.05% and a negative net margin of 184.93%.
Read the conference call transcript.

When did Rapid Micro Biosystems IPO?

Rapid Micro Biosystems (RPID) raised $125 million in an IPO on Thursday, July 15th 2021. The company issued 6,600,000 shares at $18.00-$20.00 per share.

Who are Rapid Micro Biosystems' major shareholders?

Top institutional investors of Rapid Micro Biosystems include Informed Momentum Co LLC (0.41%), Evernest Financial Advisors LLC (0.30%), Essex Investment Management Co. LLC (0.15%) and Legato Capital Management LLC (0.04%). Insiders that own company stock include Kennedy Lewis Management Lp, Robert G Jr Spignesi, Sean M Wirtjes, Richard S Kollender and Melinda Litherland Pei.
View institutional ownership trends.

How do I buy shares of Rapid Micro Biosystems?

Shares of RPID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rapid Micro Biosystems own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rapid Micro Biosystems investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Advanced Micro Devices (AMD), Black Stone Minerals (BSM), Essex Property Trust (ESS), Iovance Biotherapeutics (IOVA) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 5/09/2025
• Today: 5/14/2025
• Next Earnings (Estimated): 8/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:RPID
• CIK: 1380106
• Web: www.rapidmicrobio.com
• Phone: 978-349-3200
• Fax: N/A
• Employees: 200
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.00
• High Stock Price Target: $8.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +153.2%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 4.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-52,470,000.00
• Net Margins: -184.93%
• Pretax Margin: -184.78%
• Return on Equity: -48.05%
• Return on Assets: -39.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.52
• Quick Ratio: 4.19

Sales & Book Value

• Annual Sales: $28.05 million
• Price / Sales: 4.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.78 per share
• Price / Book: 1.14

Miscellaneous

• Outstanding Shares: 43,237,000
• Free Float: 29,952,000
• Market Cap: $136.63 million
• Optionable: Not Optionable
• Beta: 1.13